The former New England Compounding Center will pay $200 million to victims and creditors for the 2012 outbreak of meningitis that killed 64.

Symbiosis Pharmaceutical Services is now offering a new bulk lyophilization (freeze drying) service in response to increasing demand in the manufacture of bulk intermediates and APIs by lyophilization.

Janssen pledges $6 million to Rutgers CSOPS for continuous manufacturing research.

The method patent covers the infusion of bendamustine hydrochloride for the treatment of certain blood cancers.

The Critical Path Institute launched a consortium to help develop therapies for newborns.

Emergent gives ProMetic long-term access to its Winnipeg facility.

Alexion will construct a biologics facility in Ireland that is its first outside the US.

The Irish company Endo International announced that it would acquire Par Pharmaceutical for $8.05 billion.

AstraZeneca announces that it will invest $285 million in a new manufacturing facility in Sweden.

CPhI Worldwide announces the 2015 Expert Panel, including 2014 panel veterans and three new members.

Raplixa fibrin sealant, the first approved spray-dried biologic, is a hemostatic agent that helps control bleeding from small blood vessels during surgery.

SAFC’s new ADC wing in St. Louis, MO will feature commercial-scale manufacture of antibody-drug conjugates, and its Carlsbad, CA site will offer enhanced gene-therapy services.

The dinner will be held on Oct. 14, 2015 during CPhI Worldwide, at the Prado Museum in Madrid.

Supply chain consortium establishes a working group to address quality problems in India.

CPhI Istanbul to feature materials, manufacturing, packaging and contract services solutions.

FDA concludes Orkambi demonstrates a clinical benefit over placebo, but questions the magnitude of the improvement.

Pall has agreed to be acquired by Danaher for $127.20 per share.

Eli Lilly announces that it will establish a drug delivery and device center in Cambridge, Massachusetts.

Juno Therapeutics announces that it will expand its cellular therapies pipeline with the acquisition of Stage Cell Therapeutics for €52.5 million.

Pluristem Therapeutics announces that Japan’s Pharmaceuticals and Medical Devices Agency agreed with its methods for the manufacture of PLX-PAD cells.

Pfizer acquires minority equity stake in AM-Pharma and secures option to acquire remaining equity.

With acquisition of Oncaspar portfolio for leukemia from Sigma-Tau Finanziaria, Baxter BioScience adds an oncology infrastructure and biologic.

CombiLac is a lactose-based, co-processed excipient, designed to ease oral solid dosage form development and manufacture in direct compression.

The new Kaye Validator AVS combines accurate sensor measurements with all GMP requirements for calibration and traceability.

Turkey continues to dominate the MENA pharma region as regional manufactures expand at double-digit pace with the arrival of international players.

The agency publishes draft guidance answering industry questions about the Biologics Price Competition and Innovation Act.

A vaccine patch may eliminate the need for traditional means of vaccine distribution, according to an article in NPR.

FDA issues a Form 483 following inspection of Impax Laboratories' Hayward, CA facility.